Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can targeted radiation boost lung cancer treatment? 4000-patient study seeks answers.

NCT ID NCT06613633

Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 4000 people with advanced lung cancer who had a specific gene mutation (EGFR) and were taking a targeted pill. The goal was to find the best time to add focused radiation to shrink any remaining tumors. Researchers tracked when tumors shrank the most and where they were located, to see if adding radiation is a good next step.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

4,000 people

The number who actually took part.

Started

Sep 2018

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Advanced EGFR-mutant NSCLC patients receiving third-generation EGFR-TKIs are enrolled

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pathologically confirmed non-small cell lung cancer; * clinical stage IV (AJCC, 8th edition, 2017); * EGFR sensitizing mutations (L858R or 19del); * age≥18 years old; * KPS score≥70; * complete systemic imaging (including brain MRI) before third-generation EGFR-TKI treatment; * received standard third-generation EGFR-TKI therapy (monotherapy or combined with brain radiotherapy); * willing to cooperate with the follow-up after third-generation EGFR-TKI treatment; * informed consent of the patient. Exclusion Criteria: * Multiple primary or metastatic tumors (except early skin cancer, cervical carcinoma in situ that has been treated radically, with no recurrence or progression for more than 5 years); * Pregnant or lactating women who, as judged by the investigator, were not candidates for brain MRI; * Uncontrolled epilepsy, central nervous system disease, or history of mental disorders, judged by the researcher to potentially interfere with the signing of the informed consent form or affect patient compliance.; * patients without EGFR sensitive mutations or with unknown EGFR mutation status. Withdrawal criteria * The investigators considered that the patients had poor adherence to the study protocol. * The patient withdrew informed consent and asked to withdraw. * There was any safety reason (adverse event) considered by the investigator; * Due to other underlying diseases, side effects, economic factors, and other reasons, patients did not receive regular doses of third-generation EGFR-TKI (continuous withdrawal time more than 1 week, cumulative withdrawal time more than 2 weeks, etc.). * The patient was not followed up according to the protocol. * Other circumstances in which withdrawal from the study was deemed necessary by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (advanced non-small cell lung cancer) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (advanced non-small cell lung cancer) Third-generation tki

Contacts and locations

Locations

  • Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200050, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

  • Wuhan Tongji Hospital

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.